Galectin Therapeutics:Belapectin针对MASH肝硬化及门脉高压患者的C类会议获FDA积极反馈

美股速递
Jun 23

Galectin Therapeutics Inc宣布,其针对MASH肝硬化合并门脉高压患者的研究药物Belapectin,与美国食品药品监督管理局进行的C类会议取得了积极进展。此次会议为后续的临床开发路径提供了关键的监管指导。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10